Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | RPLP1 | P05386 | 1/20 | 0.45 |
| ▸ | RPLP0 | P05388 | 1/20 | 0.45 |
| ▸ | RPS17 | P08708 | 1/20 | 0.45 |
| ▸ | RPSA | P08865 | 1/20 | 0.45 |
| ▸ | RPS2 | P15880 | 1/20 | 0.45 |
| ▸ | RPL35A | P18077 | 1/20 | 0.45 |
| ▸ | RPL7 | P18124 | 1/20 | 0.45 |
| ▸ | RPL17 | P18621 | 1/20 | 0.45 |
| ▸ | RPS4Y1 | P22090 | 1/20 | 0.45 |
| ▸ | RPS3 | P23396 | 1/20 | 0.45 |
| ▸ | RPS12 | P25398 | 1/20 | 0.45 |
| ▸ | RPL13 | P26373 | 1/20 | 0.45 |
| ▸ | RPL10 | P27635 | 1/20 | 0.45 |
| ▸ | RPL12 | P30050 | 1/20 | 0.45 |
| ▸ | RPL9; RPL9P7; RPL9P8; RPL9P9 | P32969 | 1/20 | 0.45 |
| ▸ | RPL22 | P35268 | 1/20 | 0.45 |
| ▸ | RPL4 | P36578 | 1/20 | 0.45 |
| ▸ | RPS19 | P39019 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416073 | 0.88 | ALDH1A1 (0.39) | ALDH1A1LMNANPC1RAB9AMAPT | |
| SCHEMBL414720 | 0.80 | RPLP1 (0.44) | ALDH1A1RPLP1RPLP0RPS17RPSA | |
| SCHEMBL2483885 | 0.80 | MAPT (0.34) | ALDH1A1LMNARPLP1RPLP0RPS17 | |
| SCHEMBL416207 | 0.71 | MAPK1 (0.60) | ALDH1A1LMNANPC1RAB9AMAPT | |
| SCHEMBL419443 | 0.70 | ALDH1A1 (0.57) | ALDH1A1LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL415625 | 0.70 | SIGMAR1 (0.43) | ALDH1A1LMNANPC1RAB9AMAPT | |
| SCHEMBL415188 | 0.69 | ACHE (0.54) | ALDH1A1LMNANPC1RAB9AMEN1 | |
| SCHEMBL416236 | 0.69 | CLK1 (0.49) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL3113118 | 0.69 | EGFR (0.57) | — | |
| SCHEMBL3130467 | 0.68 | ALDH1A1 (0.64) | ALDH1A1LMNANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2012-01-26 | — | — | US | claimed |
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2012-01-26 | — | — | US | disclosed |
| EP-2376431-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010066847-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | CELLVIR (FR) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | HAVCR2, MAVS, EIF2AK2 | ALDH1A1 455/4885LMNA 3529/4885RPLP1 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.